Quantitative analysis of serum NfL levels using our assay successfully distinguishes between Alzheimer’s Disease patients and healthy individuals, highlighting the assay’s potential as a cost-effective, ultra-sensitive tool for clinical ND screening. This evidence concerns the gene NEFL and early-onset autosomal dominant Alzheimer disease.